There are 2185 resources available
231O - Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase III UNICANCER trial
Presenter: Sofia Rivera
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
1537O - Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC)
Presenter: Benjamin Geisler
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
LBA5 - A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
Presenter: Thomas Powles
Session: Presidential Symposium II: Practice-changing trials
Resources:
Abstract
1538O - Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study
Presenter: Alexis Cortot
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
CN29 - Short term effects of self-care behaviours on quality of life for patients on oral anticancer agents
Presenter: Marco Di Nitto
Session: MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation
Resources:
Abstract
CN47 - Consensus research priorities for cancer nursing in Europe: A Delphi study
Presenter: Amanda Drury
Session: MASCC-EONS collaborative session: Nursing researchers’ role in supportive care implementation
Resources:
Abstract
1963O - JCOG1019: An open-label, non-inferiority, randomised phase III study comparing the effectiveness of watchful waiting (WW) and intravesical Bacillus Calmette-Guérin (BCG) in patients (Pts) with high-grade pT1 (HGT1) bladder cancer with pT0 on the second transurethral resection (TUR) specimen
Presenter: Hiroshi Kitamura
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Abstract
69MO - Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort
Presenter: Christopher Douville
Session: Mini oral session: Basic science & Translational research
Resources:
Abstract
LBA60 - Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Presenter: Zhi Peng
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
347MO - The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)
Presenter: Xiaojia Wang
Session: Mini oral session 2: Breast cancer, metastatic
Resources:
Abstract